Profile - To The Moon

rajamiikaaii

Posts · 2Posts · 2
Following · 0Following · 0
Followers · 0Followers · 0

- rajamiikaaiirajamiikaaii
  ·2021-05-26
  A once in a decade opportunity to profit..
  Once-Bright Light Novavax Stares Into a Dimming Future as Vaccine Also-Ran
  Competitive pressure has put NVAX stock in a precarious situation. Much of the time, I suspect, ana
  Once-Bright Light Novavax Stares Into a Dimming Future as Vaccine Also-Ran
  250 Comment
  4
  Share
  Report
- rajamiikaaiirajamiikaaii
  ·2021-05-26
  Buy in early and trade the wave!
  You Can Afford to Be Extremely Patient With Coinbase Stock
  With Bitcoin crumbling, COIN will be deflated for a while. Cathie Wood is thematriarch of Wall Stre
  You Can Afford to Be Extremely Patient With Coinbase Stock
  453 2
  3
  Share
  Report

Most Discussed

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"isCurrentUser":false,"userPageInfo":{"id":"3584177522604135","uuid":"3584177522604135","gmtCreate":1621125154586,"gmtModify":1621247112674,"name":"rajamiikaaii","pinyin":"rajamiikaaii","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":0,"tweetSize":2,"questionSize":0,"limitLevel":999,"accountStatus":3,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[],"userBadgeCount":0,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":136891012,"gmtCreate":1622003530036,"gmtModify":1704365894138,"author":{"id":"3584177522604135","authorId":"3584177522604135","name":"rajamiikaaii","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584177522604135","authorIdStr":"3584177522604135"},"themes":[],"htmlText":"A once in a decade opportunity to profit..","listText":"A once in a decade opportunity to profit..","text":"A once in a decade opportunity to profit..","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/136891012","repostId":"1165241670","repostType":4,"repost":{"id":"1165241670","pubTimestamp":1622001160,"share":"https://ttm.financial/m/news/1165241670?lang=&edition=fundamental","pubTime":"2021-05-26 11:52","market":"us","language":"en","title":"Once-Bright Light Novavax Stares Into a Dimming Future as Vaccine Also-Ran","url":"https://stock-news.laohu8.com/highlight/detail?id=1165241670","media":"InvestorPlace","summary":"Competitive pressure has put NVAX stock in a precarious situation.\n\nMuch of the time, I suspect, ana","content":"<blockquote>\n Competitive pressure has put NVAX stock in a precarious situation.\n</blockquote>\n<p>Much of the time, I suspect, analysts who give a bearish take on a particular company do so because they have some level of disdain for it, no matter how minor. But that’s not the case with<b>Novavax</b>(NASDAQ:<b><u>NVAX</u></b>). After an initial hesitation for the investment narrative around NVAX stock, I’ve supported its bullish thesis. That change of heart came about because of the science.</p>\n<p><img src=\"https://static.tigerbbs.com/160226899c7a4d832ba23044479cfb70\" tg-width=\"300\" tg-height=\"169\" referrerpolicy=\"no-referrer\">Source: Shutterstock</p>\n<p>As you know, the biotechnology and pharmaceutical industries performed a global pivot to address the novel coronavirus pandemic. Here, the primary concern aside from safety was time. Typically,it takes years to research, develop and distribute a vaccine. We didn’t have years, we had months. Surprisingly, despite the U.S. arguably bungling the crisis, we pulled through with Operation Warp Speed.</p>\n<p>So, let’s give credit where it’s due. Personally, I thought the Trump administration handled the crisis chaotically and haphazardly. But the former president marshaled the powers of the U.S. in a most unprecedented manner. Sure enough, NVAX stock was a beneficiary. The underlying company was once on the brink of implosion. Then came Covid-19’s early attack and Novavax was one of the promising vaccine frontrunners.</p>\n<p>True, the time component I just mentioned incentivized the case for<b>Pfizer</b>(NYSE:<b><u>PFE</u></b>) and<b>Moderna</b>(NASDAQ:<b><u>MRNA</u></b>), which utilized themessenger-RNA approach. But the problem was that the Food and Drug Administration had never approved nucleic-acid-based vaccines. Though levering a tremendous rapid-manufacturing advantage, mRNA-based vaccines are experimental.</p>\n<p>That gave a distinct tip of the hat to Novavax and by logical deduction, NVAX stock. Going with asubunit approach, Novavax was working with proven and approved science. For example, the hepatitis B vaccine is a subunit type. This knowledge would also give the public some reassurances that big pharma wasn’t going to pull aDr. Frankenstein act.</p>\n<p><b>NVAX Stock Gassed Out Before the Finish</b></p>\n<p>If this were any other outbreak, I think NVAX stock would be the most compelling idea among the pharmaceutical rivals. Again, the underlying company was working with a proven platform. But safety wasn’t the only concern here. Government bodies throughout the world were under the clock to save lives.</p>\n<p>I’m not suggesting that Pfizer and Moderna compromised because science backs up their efficacy and safety claims. But the reality is that their mRNA vaccines had the rapid-manufacturing attribute that pushed them to the top. And because of this victory, it’s conceivable that the scientific community will explore mRNA vaccines as frontline solutions for the next pandemic.</p>\n<p>That’s why banking on NVAX stock to address the SARS-CoV-2 outbreak in other countries is as viable a prospect as it once was. The world watched the resounding success of Pfizer and Moderna. Yes, many hiccups occurred. Also, Pfizer’s vaccine in particular requires ultra-cold storage, which is problematic for many underfunded national healthcare systems.</p>\n<p>Nevertheless, it’s Pfizer and Moderna that got the ball rolling, with millions of people vaccinated within a year or so of the U.S. Covid crisis. Novavax on the other hand? While Novavax was performing Phase III trials, the federal governmenthad already authorized Pfizer and Moderna’s mRNA vaccinesfor emergency use.</p>\n<p>I suppose that millions of people can wait for the Novavax vaccine. But they can also look at the hundreds of millions who took the Pfizer and Moderna vaccines. Outside of a few cases of worrying side effects, mRNA vaccines have thus far proven exceptionally safe and effective.</p>\n<p>Plus, the Centers for Disease Control and Prevention recently recommended thatfully vaccinated people can largely resume normal activities. Increasingly, then, there’s less incentive to wait around for Novavax’s proven approach when the incumbents are outperforming on all core fronts.</p>\n<p><b>The Next Pandemic May Be the Kill Shot</b></p>\n<p>While virtually all Americans are undoubtedly eager to return to normal, the lessons that Covid-19 imposed should not go ignored. And if the public forgets about this crisis, the international health community certainly will not.</p>\n<p>As you might expect, epidemiologists arebusy identifying potential new viral hotspots. Of course, the philosophy here is that an ounce of prevention is worth more than a pound of cure. Still, biological threats are notoriously difficult to decipher.</p>\n<p>Should another outbreak occur, the pharmaceutical industry will be ready, with Covid-19 being a baptism of fire. But they’ll probably be ready with mRNA vaccines, not subunits. And that might turn out to be the ultimate headwind for NVAX stock.</p>\n<p><i>On the date of publication, Josh Enomotodid not have (either directly or indirectly) any positions in the securities mentioned in this article.The opinions expressed in this article are those of the writer, subject to the InvestorPlace.comPublishing Guidelines.</i></p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Once-Bright Light Novavax Stares Into a Dimming Future as Vaccine Also-Ran</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOnce-Bright Light Novavax Stares Into a Dimming Future as Vaccine Also-Ran\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-26 11:52 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/05/once-bright-nvax-stock-future-dimming/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Competitive pressure has put NVAX stock in a precarious situation.\n\nMuch of the time, I suspect, analysts who give a bearish take on a particular company do so because they have some level of disdain ...</p>\n\n<a href=\"https://investorplace.com/2021/05/once-bright-nvax-stock-future-dimming/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://investorplace.com/2021/05/once-bright-nvax-stock-future-dimming/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1165241670","content_text":"Competitive pressure has put NVAX stock in a precarious situation.\n\nMuch of the time, I suspect, analysts who give a bearish take on a particular company do so because they have some level of disdain for it, no matter how minor. But that’s not the case withNovavax(NASDAQ:NVAX). After an initial hesitation for the investment narrative around NVAX stock, I’ve supported its bullish thesis. That change of heart came about because of the science.\nSource: Shutterstock\nAs you know, the biotechnology and pharmaceutical industries performed a global pivot to address the novel coronavirus pandemic. Here, the primary concern aside from safety was time. Typically,it takes years to research, develop and distribute a vaccine. We didn’t have years, we had months. Surprisingly, despite the U.S. arguably bungling the crisis, we pulled through with Operation Warp Speed.\nSo, let’s give credit where it’s due. Personally, I thought the Trump administration handled the crisis chaotically and haphazardly. But the former president marshaled the powers of the U.S. in a most unprecedented manner. Sure enough, NVAX stock was a beneficiary. The underlying company was once on the brink of implosion. Then came Covid-19’s early attack and Novavax was one of the promising vaccine frontrunners.\nTrue, the time component I just mentioned incentivized the case forPfizer(NYSE:PFE) andModerna(NASDAQ:MRNA), which utilized themessenger-RNA approach. But the problem was that the Food and Drug Administration had never approved nucleic-acid-based vaccines. Though levering a tremendous rapid-manufacturing advantage, mRNA-based vaccines are experimental.\nThat gave a distinct tip of the hat to Novavax and by logical deduction, NVAX stock. Going with asubunit approach, Novavax was working with proven and approved science. For example, the hepatitis B vaccine is a subunit type. This knowledge would also give the public some reassurances that big pharma wasn’t going to pull aDr. Frankenstein act.\nNVAX Stock Gassed Out Before the Finish\nIf this were any other outbreak, I think NVAX stock would be the most compelling idea among the pharmaceutical rivals. Again, the underlying company was working with a proven platform. But safety wasn’t the only concern here. Government bodies throughout the world were under the clock to save lives.\nI’m not suggesting that Pfizer and Moderna compromised because science backs up their efficacy and safety claims. But the reality is that their mRNA vaccines had the rapid-manufacturing attribute that pushed them to the top. And because of this victory, it’s conceivable that the scientific community will explore mRNA vaccines as frontline solutions for the next pandemic.\nThat’s why banking on NVAX stock to address the SARS-CoV-2 outbreak in other countries is as viable a prospect as it once was. The world watched the resounding success of Pfizer and Moderna. Yes, many hiccups occurred. Also, Pfizer’s vaccine in particular requires ultra-cold storage, which is problematic for many underfunded national healthcare systems.\nNevertheless, it’s Pfizer and Moderna that got the ball rolling, with millions of people vaccinated within a year or so of the U.S. Covid crisis. Novavax on the other hand? While Novavax was performing Phase III trials, the federal governmenthad already authorized Pfizer and Moderna’s mRNA vaccinesfor emergency use.\nI suppose that millions of people can wait for the Novavax vaccine. But they can also look at the hundreds of millions who took the Pfizer and Moderna vaccines. Outside of a few cases of worrying side effects, mRNA vaccines have thus far proven exceptionally safe and effective.\nPlus, the Centers for Disease Control and Prevention recently recommended thatfully vaccinated people can largely resume normal activities. Increasingly, then, there’s less incentive to wait around for Novavax’s proven approach when the incumbents are outperforming on all core fronts.\nThe Next Pandemic May Be the Kill Shot\nWhile virtually all Americans are undoubtedly eager to return to normal, the lessons that Covid-19 imposed should not go ignored. And if the public forgets about this crisis, the international health community certainly will not.\nAs you might expect, epidemiologists arebusy identifying potential new viral hotspots. Of course, the philosophy here is that an ounce of prevention is worth more than a pound of cure. Still, biological threats are notoriously difficult to decipher.\nShould another outbreak occur, the pharmaceutical industry will be ready, with Covid-19 being a baptism of fire. But they’ll probably be ready with mRNA vaccines, not subunits. And that might turn out to be the ultimate headwind for NVAX stock.\nOn the date of publication, Josh Enomotodid not have (either directly or indirectly) any positions in the securities mentioned in this article.The opinions expressed in this article are those of the writer, subject to the InvestorPlace.comPublishing Guidelines.","news_type":1},"isVote":1,"tweetType":1,"viewCount":250,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":136899531,"gmtCreate":1622003481623,"gmtModify":1704365892175,"author":{"id":"3584177522604135","authorId":"3584177522604135","name":"rajamiikaaii","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584177522604135","authorIdStr":"3584177522604135"},"themes":[],"htmlText":"Buy in early and trade the wave!","listText":"Buy in early and trade the wave!","text":"Buy in early and trade the wave!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/136899531","repostId":"1130362459","repostType":4,"repost":{"id":"1130362459","pubTimestamp":1622000928,"share":"https://ttm.financial/m/news/1130362459?lang=&edition=fundamental","pubTime":"2021-05-26 11:48","market":"us","language":"en","title":"You Can Afford to Be Extremely Patient With Coinbase Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=1130362459","media":"InvestorPlace","summary":"With Bitcoin crumbling, COIN will be deflated for a while.\n\nCathie Wood is thematriarch of Wall Stre","content":"<blockquote>\n <b>With Bitcoin crumbling, COIN will be deflated for a while.</b>\n</blockquote>\n<p>Cathie Wood is thematriarch of Wall Street. She delivers results for her clients while doing so in an ethical manner. Even if you’re not a money person, you got to respect Wood. Despite my reverence, though, I’ve got to question her decision to buy<b>Coinbase</b>(NASDAQ:<b><u>COIN</u></b>).</p>\n<p><img src=\"https://static.tigerbbs.com/f8c8b9616b33c8206aa3edc5c595e8ef\" tg-width=\"300\" tg-height=\"169\" referrerpolicy=\"no-referrer\">Source: Primakov / Shutterstock.com</p>\n<p>Yes, COIN stock is on discount but not all markdowns are worth considering.</p>\n<p>Let’s back up a step. Technically, I’m referring to Barron’s post on May 21, which revealed that Wood’s ARK Invest fund “snapped up more than 1.2 million additional shares, lifting its total holdings by more than 40% to 4.2 million shares.”</p>\n<p>Most of the shares went to the fund’s flagship<b>ARK Innovation ETF</b>(NYSEARCA:<b><u>ARKK</u></b>).</p>\n<p>On the surface, I can understand why Wood jumped on the Coinbase dip. After all, the Oracle of Omaha Warren Buffett once stated in part, “be fearful when others are greedy andgreedy only when others are fearful.”</p>\n<p>Well, I think we can safely say that there’s a lot of fear going on in the crypto space. Therefore, if we apply Buffett’s words literally, now is the perfect time to invest in Coinbase stock, but is it really?</p>\n<p>Take it from a cryptocurrency advocate and investor. I’ve gone through multiple boom-bust cycles with this temptress known as<b>Bitcoin</b>(CCC:<b><u>BTC-USD</u></b>).</p>\n<p>As I shared with the<i>InvestorPlace</i>audience,I’m mortgage-free because of cryptocurrencies, and now I’m on the cusp of being able to buy back the cryptocurrencies I used to pay off my house.</p>\n<p>Seriously, I should have had my own crypto research project. I could have told you when to get in and, more importantly, when to get out. Because that’s where the problem with cryptos and by logical deduction, Coinbase stock lies.</p>\n<p>Too many people gambled on fantasies rather than realities.</p>\n<p><b>Coinbase Is a Long-Term Investment That You Can Wait on</b></p>\n<p>Frankly, the online publishing industry is ill-suited for cryptocurrency coverage. Editorial staffs must schedule story assignments, submitted works must undergo an editing process and once everything looks kosher, the piece goes live.</p>\n<p>But the challenge here is by the time crypto-related content goes through this normal procedure, everything could have changed. Indeed, the narrative for Bitcoin took only an hour or so to spark the negativity that it did.</p>\n<p>That segues into another point about virtual currencies — you’ve got to stay agile. This is a sector that will humble as quickly as it crowns you a genius. Something like Coinbase stock is especially at risk because it’s an equity unit that follows traditional market rules, yet is inextricably tied to an unprecedented, decentralized platform.</p>\n<p>This leads me to one hard conclusion: Coinbase stock is a long-term investment. That doesn’t mean you should buy shares today.</p>\n<p>Given the extreme velocity of Bitcoin’s correction, we can reasonably surmise that it’s going through thetypical process of a bear market bust cycle. You can read about the various emotional ranges on the link provided but I don’t think that we’ve yet to reach capitulation. If we haven’t reached capitulation, the market has yet to find a bottom, not even close.</p>\n<p>While I don’t have proof, some compelling evidence suggests that market cycles work through natural sequences. One of the most powerful is the Fibonacci sequence. From Bitcoin’s peak price of approximately $64,529, here are the numbers to watch.</p>\n<ul>\n <li>8% retracement: $39,879</li>\n <li>50% retracement (an “unofficial” Fib level): $32,264</li>\n <li>2% retracement: $24,650</li>\n <li>6% retracement: $15,229</li>\n</ul>\n<p>Interestingly, when the<b>Nasdaq Composite</b>index hit a weekly average high of nearly 4,915 points during the euphoria of the 2000 tech bubble, it eventually found a bottom at just under 1,140 points, a 23.2% decline.</p>\n<p>Therefore, I see the bottom of Bitcoin at around $15,000, which means theoretically, Coinbase stock has much more to fall.</p>\n<p><b>You Got to Know the Game</b></p>\n<p>One of the unsavory elements of the crypto game is the proliferation of narrative frontrunners. When you hear talk about Bitcoin killing the central banks, the only thing you should do is run. Nothing is more dangerous than believing an idea that has no fundamental merit.</p>\n<p>Essentially, people got gamed. Personally, I thought that Bitcoin was going to $100,000 earlier this year, but when BTC struggled, that was when I had doubts. So I made sure to cash out a good chunk of my portfolio because I knew that no market is immune from the treachery of human emotions.</p>\n<p>As harsh as this correction is, it’s a lesson. Never believe that any asset is different, whether you’re talking Bitcoin, real estate or used car prices. Nothing can run up forever.</p>\n<p>But if you’re going to ignore this teaching moment, for goodness’ sake, don’t rush into Coinbase stock before performing due diligence. With the equity unit so tied to Bitcoin’s fortunes, this is not the time to bet the house on it.</p>\n<p><i>On the date of publication, Josh Enomoto&nbsp;held a LONG position in&nbsp;BTC.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.comPublishing Guidelines.</i></p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>You Can Afford to Be Extremely Patient With Coinbase Stock</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nYou Can Afford to Be Extremely Patient With Coinbase Stock\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-26 11:48 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/05/you-can-afford-patience-with-coinbase/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>With Bitcoin crumbling, COIN will be deflated for a while.\n\nCathie Wood is thematriarch of Wall Street. She delivers results for her clients while doing so in an ethical manner. Even if you’re not a ...</p>\n\n<a href=\"https://investorplace.com/2021/05/you-can-afford-patience-with-coinbase/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"COIN":"Coinbase Global, Inc."},"source_url":"https://investorplace.com/2021/05/you-can-afford-patience-with-coinbase/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1130362459","content_text":"With Bitcoin crumbling, COIN will be deflated for a while.\n\nCathie Wood is thematriarch of Wall Street. She delivers results for her clients while doing so in an ethical manner. Even if you’re not a money person, you got to respect Wood. Despite my reverence, though, I’ve got to question her decision to buyCoinbase(NASDAQ:COIN).\nSource: Primakov / Shutterstock.com\nYes, COIN stock is on discount but not all markdowns are worth considering.\nLet’s back up a step. Technically, I’m referring to Barron’s post on May 21, which revealed that Wood’s ARK Invest fund “snapped up more than 1.2 million additional shares, lifting its total holdings by more than 40% to 4.2 million shares.”\nMost of the shares went to the fund’s flagshipARK Innovation ETF(NYSEARCA:ARKK).\nOn the surface, I can understand why Wood jumped on the Coinbase dip. After all, the Oracle of Omaha Warren Buffett once stated in part, “be fearful when others are greedy andgreedy only when others are fearful.”\nWell, I think we can safely say that there’s a lot of fear going on in the crypto space. Therefore, if we apply Buffett’s words literally, now is the perfect time to invest in Coinbase stock, but is it really?\nTake it from a cryptocurrency advocate and investor. I’ve gone through multiple boom-bust cycles with this temptress known asBitcoin(CCC:BTC-USD).\nAs I shared with theInvestorPlaceaudience,I’m mortgage-free because of cryptocurrencies, and now I’m on the cusp of being able to buy back the cryptocurrencies I used to pay off my house.\nSeriously, I should have had my own crypto research project. I could have told you when to get in and, more importantly, when to get out. Because that’s where the problem with cryptos and by logical deduction, Coinbase stock lies.\nToo many people gambled on fantasies rather than realities.\nCoinbase Is a Long-Term Investment That You Can Wait on\nFrankly, the online publishing industry is ill-suited for cryptocurrency coverage. Editorial staffs must schedule story assignments, submitted works must undergo an editing process and once everything looks kosher, the piece goes live.\nBut the challenge here is by the time crypto-related content goes through this normal procedure, everything could have changed. Indeed, the narrative for Bitcoin took only an hour or so to spark the negativity that it did.\nThat segues into another point about virtual currencies — you’ve got to stay agile. This is a sector that will humble as quickly as it crowns you a genius. Something like Coinbase stock is especially at risk because it’s an equity unit that follows traditional market rules, yet is inextricably tied to an unprecedented, decentralized platform.\nThis leads me to one hard conclusion: Coinbase stock is a long-term investment. That doesn’t mean you should buy shares today.\nGiven the extreme velocity of Bitcoin’s correction, we can reasonably surmise that it’s going through thetypical process of a bear market bust cycle. You can read about the various emotional ranges on the link provided but I don’t think that we’ve yet to reach capitulation. If we haven’t reached capitulation, the market has yet to find a bottom, not even close.\nWhile I don’t have proof, some compelling evidence suggests that market cycles work through natural sequences. One of the most powerful is the Fibonacci sequence. From Bitcoin’s peak price of approximately $64,529, here are the numbers to watch.\n\n8% retracement: $39,879\n50% retracement (an “unofficial” Fib level): $32,264\n2% retracement: $24,650\n6% retracement: $15,229\n\nInterestingly, when theNasdaq Compositeindex hit a weekly average high of nearly 4,915 points during the euphoria of the 2000 tech bubble, it eventually found a bottom at just under 1,140 points, a 23.2% decline.\nTherefore, I see the bottom of Bitcoin at around $15,000, which means theoretically, Coinbase stock has much more to fall.\nYou Got to Know the Game\nOne of the unsavory elements of the crypto game is the proliferation of narrative frontrunners. When you hear talk about Bitcoin killing the central banks, the only thing you should do is run. Nothing is more dangerous than believing an idea that has no fundamental merit.\nEssentially, people got gamed. Personally, I thought that Bitcoin was going to $100,000 earlier this year, but when BTC struggled, that was when I had doubts. So I made sure to cash out a good chunk of my portfolio because I knew that no market is immune from the treachery of human emotions.\nAs harsh as this correction is, it’s a lesson. Never believe that any asset is different, whether you’re talking Bitcoin, real estate or used car prices. Nothing can run up forever.\nBut if you’re going to ignore this teaching moment, for goodness’ sake, don’t rush into Coinbase stock before performing due diligence. With the equity unit so tied to Bitcoin’s fortunes, this is not the time to bet the house on it.\nOn the date of publication, Josh Enomoto held a LONG position in BTC. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.comPublishing Guidelines.","news_type":1},"isVote":1,"tweetType":1,"viewCount":453,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"posts","isTTM":true}